GlassScriptPhysician profile
Elie Mansour
NPI 1942246145
$4,229.89
in general payments reported to CMS, 2019-2025
32 companies · $329 in 2025
The $329 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $662 · 2021: $870 · 2022: $618 · 2023: $293 · 2024: $498 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $1,540.42 | 2019-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $524.49 | 2019-2024 | Farxiga, Bevespi Aerosphere, Breztri |
| Glaxosmithkline, LLC. | $248.87 | 2019-2025 | Nucala |
| Zimmer Biomet Holdings, INC. | $192.26 | 2024 | Avenir |
| Stryker Corporation | $165.94 | 2024 | Mako, Triathlon |
| Actelion Pharmaceuticals US, INC. | $165.28 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $134.23 | 2021-2023 | Acthar |
| Sonex Health, INC. | $130.59 | 2025 | Sx-One Microknife |
| Shire North American Group INC | $128.76 | 2019 | |
| Sunovion Pharmaceuticals INC. | $111.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.46 | 2021-2022 | |
| Insmed, INC. | $79.70 | 2020-2022 | |
| Genzyme Corporation | $71.00 | 2019 | |
| Inogen, INC. | $68.16 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Janssen Pharmaceuticals, INC | $53.70 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.23 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $49.38 | 2022-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $46.31 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.06 | 2021 | |
| Scilex Pharmaceuticals INC. | $41.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.37 | 2019 | |
| Philips North America LLC | $36.59 | 2019 | |
| Mylan Specialty L.P. | $36.12 | 2019-2022 | |
| Verona Pharma, INC. | $35.22 | 2025 | Ohtuvayre |
| Amarin Pharma, INC. | $28.39 | 2019 | |
| Pfizer INC. | $25.20 | 2019-2020 | |
| Esperion Therapeutics, INC. | $22.69 | 2021 | |
| Advanced Respiratory, INC | $19.11 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.58 | 2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $14.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.59 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elie Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.